
The FDA approves durvalumab for bladder cancer and gefurulimab for myasthenia gravis, creating distinct ADC, biologic, and autoinjector production needs.
Click the title above to open the Pharmaceutical Technology May 2018 issue in an interactive PDF format.
over 8 years ago
Microfluidics Platform for Drug Encapsulationover 8 years ago
Pipette Tip for Highly Viscous Liquidsover 8 years ago
PLC System With Wireless Connectionover 8 years ago
Hygienic Magnetic Mixerover 8 years ago
The Role of Carriers in DPI Capsulesover 8 years ago
Freeze-Drying Process Optimizationover 8 years ago
Harmonizing GMP Inspectionsover 8 years ago
Improving Visual Inspectionover 8 years ago
How to Plan Smoke Studiesover 8 years ago
Integrated Systems Aid Data Integrity





